@wattiez - Total acquisition cost for Diasource was €15,400,000...

@wattiez -

Total acquisition cost for Diasource was €15,400,000

Net Cash paid to Diasource was €5,293,452 (Cash generated from 2015 Calendar Year €2,406,548 )

Vendor Financing was for €7,700,000 Euro

Earn out at Annual Report estimated at €3,445,398

The first vendor financing payment was made in July 2016 of €962,500 plus interest

The next payment of €962,500 is due in Jan 2017 and can be paid out of Diasource free cash

So total net cost Anteo paid assuming this earnout amount is

= €5,293,452 (Paid in cash out of Rights Issue Dec 2015)

+ €7,700,000 + €3,445,398

= €16,438,850 = $23,305,946 AUD

Diasource Revenue January - June 2016 €8,068,056

Profit on this 6 month period was €783,191

Adding in the $2m usd Egyptian government contract and current growth my guesses are annual profits are in the range of €1,750,000 to €2,000,000 ($2.5m - $2.8m AUD Profit pa)

Anteo at its lowest prior to BBI or POC1 averaged a mcap of around $40m AUD (2011 - 2013)

This was prior to the working partnerships with Cook Medical

Prior to Anteo partnering with ATOMO to develop a Troponin POC test into the $470m AUD Cardiac POC market

Prior to Anteo partnering with ELLUME to develop the POC Flu test and others which has been through Clinical trials with Anteos teschnology

Prior to Anteo partnering with PLANET INNOVATION to develop the NPLEX Point of Care device

Partnering with the DMTC - Defence Materials Technology Centre“This represents the first step in moving into the Medical Countermeasures Program that is administered through the DMTC

So IMO while Anteo was backed into a corner as a result of poor funding choices with the Canadian CN and then having to use Bergen they are now in a much stronger position

Undervalued until debt is sorted then it is a new game

There are enough common players involved that would be more than interested in Anteo now IMO